Acorda boosts sales forecast on Ampyra; Shire looks to sleepiness use for Vyvanse;

@FiercePharma: Architects reveal renderings of new Roche HQ building. News | Follow @FiercePharma 

> Acorda Therapeutics forecast better-than-expected quarterly sales for Ampyra, its new drug to treat walking difficulties in patients with multiple sclerosis. News

> Shire plans to review development pathways with health authorities for Vyvanse as a possible treatment option for excessive daytime sleepiness. Report

> Abbott Laboratories won European approval for its bioabsorbable stent, the first such heart device that disappears after being used to prop open an artery cleared of blockages. Story

> Records show the FDA helped Arizona and California get a quick overseas source of a hard-to-find execution drug even as the agency declared it wouldn't regulate or block the imports. Item

> Four industry trade associations in the U.K., including the pharma body ABPI, have banded together to form a new lobbying group representing life sciences. Report

> Watson Laboratories got the FDA nod for the generic equivalent to Cephalon's Fentora tablets, used to treat breakthrough cancer pain. Article

> Bayer HealthCare sought to reassure healthcare professionals and their patients that a recall of alcohol prep pads distributed with its multiple sclerosis drug did not affect the drug itself. Story

> Merck KGaA announced that it has bought Beijing Skywing Technology, a supplier of cell-culture media products, related technical services and bioreactors for the Chinese biopharmaceutical industry. Report

Biotech News

 @FierceBiotech: Epizyme lands $650M GSK deal

 @JohnCFierce: Planning a fierce happy hour for tweet fans on Wednesday, hosted by fierce publisher @arsalanFierce. Details to come. Follow @JohnCFierce

> CVRs: The next big thing in biotech deals? Report

> Rib-X's antibiotic pipeline garners $20M in funding. Story 

> PPD, Taijitu form new joint venture. Item 

> Lilly, Boehringer team on diabetes venture. News 

Biotech Research News

> Poverty may hold back kids' genetic potential. Story

> Study to follow kids' health from before birth to 21. Item 

> Pharma R&D changing for upcoming patent crisis. News 

> Stem cells from unfertilized eggs may produce new gene therapy. Report 

> New biological systems grown from man-made proteins. Article 

> 'Fishing' expedition might lead to early detection of Alzheimer's. Story

Manufacturing News

> Tweak push vs. pull for supply chain benefit. Story 

> USP revision aids PET drug prep. News 

> Savient to run $10M revalidation at Merck CMO. Item 

> Phony FDA agents assess fines for online drug purchases. Report 

> UK driving school fronts execution drug wholesaler. Story

> Eight critical after phosgene leak at Wanbei Pharma. News 

And Finally... A study of antibodies from people infected with H1N1 swine flu adds proof that scientists are closing in on a "universal" flu shot that could neutralize many types of flu strains. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.